FENC / Fennec Pharmaceuticals - Biopharma

RESEARCH TRIANGLE PARK, N.C., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pha more_horizontal

RESEARCH TRIANGLE PARK, N.C., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pha more_horizontal

Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Robert Andrade - Chief Fina more_horizontal

RESEARCH TRIANGLE PARK, N.C., July 31, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pha more_horizontal

Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Robert Andrade - Chief Financ more_horizontal

Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compar more_horizontal

RESEARCH TRIANGLE PARK, N.C., May 08, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty phar more_horizontal

Adherex Technologies Inc. (FENC) delivered earnings and revenue surprises of -8.33% and 100%, respectively, for the quarter ended December 2022. Do th more_horizontal